---
document_datetime: 2023-09-21 17:53:20
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/docetaxel-mylan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: docetaxel-mylan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1447998
conversion_datetime: 2025-12-21 19:12:17.598501
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Docetaxel Mylan

<!-- image -->

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------|
| IB/0006              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product | 11/08/2014                          |                                                | SmPC                             |           |
| IB/0004              | Update of section 4.4 and 4.5 of the SmPC in order to add a warning and update the safety information on                                                                                                                                                             | 19/03/2014                          | 03/06/2014                                     | SmPC                             |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

Medicinal product no longer authorised

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | interactions with CYP3A4 inhibitors further to the PRAC assessment of a signal. In addition, some inconsistencies have been rectified on the number and grade of alopecia adverse reactions in section 4.8 of the SmPC. Finally, minor linguistic amendments have been performed in BG, CS, DA,DE, ES, ET, FR, HU, HR, IT, LT, LV, MT, NO, PL, SK AND SV in order to align the annexes to the same language annexes of the originator Taxotere. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                  | longer authorised         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| IB/0003/G | This was an application for a group of variations. To update section 4.4 to add warning on cystoid macular oedema based on the results of safety cumulative reviews conducted by the innovator's MAH and section 4.8 of the SmPC to include cystoid macular oedema and hyponatraemia in the list of adverse reactions following assessment by the CHMP for the originator product Taxotere. The Package Leaflet is updated accordingly. In addition the product information has been brought in line with the latest QRD version 9.0. Finally the contact details for the New Member State Croatia has been added to the list of local representatives in the Package Leaflet and the names of Bulgaria, Hungary, Greece and Cyprus have been corrected and written in their national languages. 18/11/2013 Medicinal product | 03/06/2014 SmPC and PL no |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                     | longer authorised                              |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| IB/0002 | Update of the SmPC for Docetaxel Mylan following assessment of the same changes for the reference product, Taxotere. Sections 4.4 and 4.8 of the SPC are updated in order to add a warning related to respiratory disorders and to include interstitial pneumonitis, interstitial lung disease and pulmonary fibrosis as new adverse reactions observed the post-marketing setting following a relevant cumulative review of the originator product's safety database. The Package Leaflet is updated accordingly. The MAH has also taken the opportunity to update the Product Information according to the latest QRD template, version 9. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH Medicinal product | 13/06/2013 03/06/2014 SmPC, Annex II and PL no |

<div style=\"page-break-after: always\"></div>

| IB/0001   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH   | 24/05/2012   | n/a   | SmPC, Labelling and PL   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------------------|

## Labelling and PL Medicinal product no longer authorised